News | November 01, 2021
GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Gini Health works in the domain of personalised healthcare
Acute therapies continue to report strong growth compared to chronic ones.
This strategic collaboration will enable continued innovation in cancer care
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
Subscribe To Our Newsletter & Stay Updated
